ABSTRACT
The FDA has approved brexanolone specifically for treatment of adults with postpartum depression (PPD). Administered I.V., it can relieve severe signs and symptoms of PPD within days rather than weeks. This article discusses the benefits and risks of brexanolone as a treatment for PPD, including nursing considerations and patient teaching.
Subject(s)
Depression, Postpartum/drug therapy , Depression, Postpartum/nursing , Pregnanolone/therapeutic use , beta-Cyclodextrins/therapeutic use , Adult , Drug Approval , Drug Combinations , Female , Humans , Patient Education as Topic , Pregnanolone/adverse effects , Risk Assessment , United States , United States Food and Drug Administration , beta-Cyclodextrins/adverse effectsSubject(s)
HIV Infections/prevention & control , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Post-Exposure Prophylaxis , Centers for Disease Control and Prevention, U.S. , Clinical Protocols , HIV Infections/transmission , Humans , Occupational Exposure , Safety , United StatesABSTRACT
Behavioral and Psychological Symptoms of Dementia (BPSD) include behaviors such as aberrant motor behavior, agitation, anxiety, apathy, delusions, depression, disinhibition, elation, hallucinations, irritability, and sleep or appetite changes. A student-led project to provide sensory stimulation in the form of "fidget blankets" developed into a community outreach program. The goal was to decrease the use of antipsychotics used for BPSD.
